Clinical Trial

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Study acronym: STAR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2019-08-22; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2025-08-28
Status change: Not Yet Recruiting → Recruiting 2020-03-03
Trial Details
NCT Number NCT04068753
Lead Sponsor University of Oklahoma
Collaborators: Tesaro, Inc.
Conditions Recurrent Cervix Cancer, Progressive Cervix Cancer
Enrollment 66 participants
Start Date 2020-02-26
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-10